Tue, Jul 22, 2014, 5:18 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Avanir Pharmaceuticals, Inc. Message Board

  • horcents@sbcglobal.net horcents Mar 3, 2013 1:25 PM Flag

    Subject

    Ray, at the risk of being overly critical of your selective postings let me point out AGAIN that you are trying to imply a knowledge you do not possess. You say the 'mechanism' that causes PBA in stroke patients 'may' be different from what causes it in ALS, etc. Ok, the mechanism may be different but the outcome is the same. If we're dealing in what "MAY" be true it is more likely N has the same palliative affect on one as the other.

    Additionally, because the drug has been shown to be diognostic by application and very fast acting it's not a huge stretch to believe the EU board would believe it makes complete sense to give it a broad label. It's so funny how you try to cast yourself as some kind of expert in brain function knowledge when you admitted the breadth and scope of your knowledge comes from something called, "Brain Physiology for Dummies", later ammended to some other equally pedestrian publication.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "It's so funny how you try to cast yourself as some kind of expert in brain function knowledge when you admitted the breadth and scope of your knowledge comes from something called, "Brain Physiology for Dummies", later ammended to some other equally pedestrian publication."
      You are lying about me admitting any such thing because it is totally false. You're quite mistaken about the "breadth and scope" of my knowledge. I'm not claiming to be the world's leading expert on the subject but I guarantee you'd be surprised at the amount of study, training and experience I've had with the subject.
      I only recommended the introductory book, Neuroanatomy Made Ridiculously Simple to you and others as an easy way for anyone to learn the basics of neuroanatomy because you scoffed at my statement that the central nervous system runs like an electrical system

    • "You say the 'mechanism' that causes PBA in stroke patients 'may' be different from what causes it in ALS, etc. Ok, the mechanism may be different but the outcome is the same. If we're dealing in what "MAY" be true it is more likely N has the same palliative affect on one as the other."
      I don't entirely agree because there may be different causes of PBA from different parts of the brain, using different neurotransmitters, depending on the type of underlying neurologic disease. And it is not to be expected that the neurons in one part of the brain, influenced by one or two neurotransmitters, are likely to be effectively treated just like the neurons in another part of the brain influenced by a different neurotransmitter or two.
      A regulatory body like the European equivalent of the FDA may want to at least have SOME (as opposed to none) objective confirmation that PBA is adequately treated in different populations by studies of those populations.
      It could go either way because the FDA has already ruled one way and they are reasonable scientists, but it can not be assumed that the Europeans, guided by a different set of realities now that the drug has been developed, will rule the same way. This commonsense idea and plausible outcome should not be so easily dismissed by some here.
      "Additionally, because the drug has been shown to be diagnostic by application and very fast acting it's not a huge stretch to believe the EU board would believe it makes complete sense to give it a broad label."
      Actually, that's not a factor in approval. The drug is not being approved as a "diagnostic" test, it is up for approval as only as a treatment. And, no, response to dex/quin is not a diagnostic for PBA. PBA responds to placebo also.
      Besides that, one thing has nothing to do with the other..

 
AVNR
5.28-0.04(-0.75%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.